July 28, 2007Diabetes Care
Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome
Key result
Fenofibrate therapy significantly reduced fasting triglycerides (-46.1%, P<0.0001) and postprandial triglycerides (-45.4%, P<0.0001) in subjects with hypertriglyceridemia and metabolic syndrome.
Why the study?
Does fenofibrate 160 mg/day improve fasting and postprandial lipoproteinemia, oxidative stress, and inflammatory markers in subjects with hypertriglyceridemia and metabolic syndrome?
Population
59 subjects with fasting hypertriglyceridemia and two or more of the Adult Treatment Panel III criteria for…
Comparison
Fenofibrate 160 mg/day vs Placebo
Design
RCT, randomly assigned, double-blind
Authors
Discussion
Loading...
Member takes
Implication
Supports fenofibrate for hypertriglyceridemia in metabolic syndrome; extends evidence to postprandial triglyceride reduction.
Key Points
- This study aims to evaluate the impact of fenofibrate on lipoproteins, oxidative stress, and inflammatory markers in subjects with hypertriglyceridemia and metabolic syndrome.
- Randomly assigned 59 subjects with fasting hypertriglyceridemia to receive fenofibrate (160 mg/day) or placebo in a double-blind clinical trial.
- Measured fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators before and after treatment.
- Fenofibrate reduced fasting triglycerides by 46.1% (P < 0.0001) and postprandial triglycerides by 45.4% (P < 0.0001).
- There was a 19.0% reduction in fasting total LDL particles (P = 0.0033), with a 40.3% reduction in small LDL particles (P < 0.0001).
- Treatment led to a 15.3% reduction in fasting oxidized fatty acids (P = 0.0013) and a 31.0% reduction in postprandial oxidized fatty acids (P < 0.0001).
Study Design
Type
RCT (n=59)
Blinding
Double-blind
Randomization
randomly assigned
Structured PICO
Does fenofibrate 160 mg/day improve fasting and postprandial lipoproteinemia, oxidative stress, and inflammatory markers in subjects with hypertriglyceridemia and metabolic syndrome?
P
Population
59 subjects with fasting hypertriglyceridemia and metabolic syndrome.
I
Intervention
Fenofibrate 160 mg/day
C
Comparator
Placebo
O
Outcome
Fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediatorssurrogate
Main Result
Effect estimate: -46.1% reduction
p-value: p=< 0.0001
Fenofibrate significantly reduces fasting and postprandial triglycerides, oxidized fatty acids, and inflammatory markers in patients with hypertriglyceridemia and metabolic syndrome.
Cite This Study
Rosenson et al. (2007) conducted an RCT in Hypertriglyceridemia and the metabolic syndrome (n=59). Fenofibrate vs. Placebo was evaluated on Fasting triglycerides (-46.1% reduction, p=< 0.0001). Fenofibrate therapy significantly reduced fasting triglycerides (-46.1%, P<0.0001) and postprandial triglycerides (-45.4%, P<0.0001) in subjects with hypertriglyceridemia and metabolic syndrome.